💡 OneSource's partner secured tentative FDA approval for generic Ozempic, positioning the company as manufacturing partner for a major drug.
What Happened
OneSource Specialty Pharma Limited announced that its partner Orbicular Pharmaceutical Technologies, together with its U.S.-based front-end partner, has secured tentative U.S. FDA approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic® (Semaglutide Injection). OneSource serves as the contract development and manufacturing organization (CDMO) partner for this product, providing end-to-end manufacturing capabilities from its US-FDA approved flagship site in Bangalore.
Key Details
- Company: OneSource Specialty Pharma Limited
- Event Type: Regulatory
- Filing Date: 21-Apr-2026 08:23:31
- NSE Filing: View Document
Why It Matters
This regulatory milestone represents a significant validation of OneSource's CDMO capabilities and positions the company as a manufacturing partner for a high-demand pharmaceutical product. Ozempic is a major blockbuster drug for diabetes and weight loss, and the tentative approval for a generic version creates potential future revenue streams for OneSource through manufacturing contracts. The announcement demonstrates the company's ability to support complex peptide manufacturing and strengthens its position in the global CDMO market for specialty pharmaceuticals and complex injectables.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free